RESUMO
Los plátanos pertenecientes al género Musa spp. ABB han sido utilizados para el tratamiento de la inflamación y el dolor. La búsqueda de antiinflamatorios de origen natural, más que una alternativa, constituye una terapia complementaria del tratamiento de la inflamación, ya que los antiinflamatorios no esteroideos son los más utilizados para enfermedades inflamatorias agudas o crónicas, pero a la vez presentan efectos secundarios gastrointestinales, cardiovasculares y renales, por lo que no es recomendable su uso prolongado. En este trabajo se ofrece información actualizada sobre los efectos farmacológicos y los metabolitos secundarios del grupo Musa spp. ABB, para su uso en la elaboración de un medicamento antiinflamatorio. Los procedimientos realizados incluyen el análisis documental y bibliográfico -en bases de datos- de artículos científicos, tesis doctorales y comunicaciones científicas; el registro de la información, y la elaboración del artículo científico, teniendo en cuenta la actualización de la información y los sitios donde se promueve la misma. Se han comprobado, a partir de extractos acuosos y alcohólicos de la planta, efectos farmacológicos tales como antiinflamatorio, antioxidante, analgésico, gastroprotector, inmunomodulador, antidiabético, anticancerígeno, antibacteriano, antiviral, hipolipemiante, antidiarreico, antihipertensivo, hepatoprotector, cicatrizante, antiulceroso y antifúngico. Los efectos antiinflamatorios y antioxidantes están relacionados con la presencia de fenoles, ácidos fenólicos, flavonoides, fitoesteroles y carotenos. Es muy limitado el empleo de extractos del grupo Musa spp. ABB en medicamentos, de ahí la propuesta de desarrollar una crema antiinflamatoria como alternativa o complemento para el tratamiento de múltiples enfermedades inflamatorias.
Plantains belonging to the genus Musa spp. ABB have been used for the treatment of infection and pain. The search for anti-inflammatories of natural origins, more than an alternative, is a complementary therapy for the treatment of inflammation, since non-steroidal anti-inflammatories are the most used for acute or chronic inflammatory diseases, but at the same time they present gastrointestinal, cardiovascular and renal side effects, so their prolonged use is not recommended. In this paper, updated information is provided on the pharmacological effects and secondary metabolites of the Musa ssp. ABB group, for its use in elaborating an anti-inflammatory drug. The procedures carried out include documental and bibliographic analysis -in databases-of scientific articles, doctoral theses and scientific communications; the information record and preparation of the article taking into account the information updating and the sites where it is supported. From aqueous and alcoholic extracts of the plant, the following effects were proven: anti-inflammatory, antioxidant, analgesic, gastro-protective, inmuno-modulator, antidiabetic, anticancer, antibacterial, antiviral, lipid-lowering, antidiarrheal, antihypertensive, hepatoprotective, healing, anti-ulcerative and antifungal. The anti-inflammatory and antioxidant effects are related to the presence of phenols, phenolic acids, flavonoids, phytosterols and carotenes. The use of Musa spp. ABB group in drugs is very limited, therefore the proposal of developing an anti-inflammatory cream to treat multiple inflammatory diseases.
RESUMO
INTRODUCTION: The incidence of clozapine-associated myocarditis varies by country. These variations were explored in VigiBase, the World Health Organization's global database which has >25 million spontaneously reported adverse drug reaction (ADR) reports from 145 national drug agencies. METHODS: On January 15, 2021, a search of VigiBase since inception focused on myocarditis in clozapine patients. The 3572 individual reports were studied using the standard VigiBase logarithmic measure of disproportionality called information component (IC). The IC measures the disproportionality between the expected and the reported rates. After duplicates were eliminated there were 3274 different patients with myocarditis studied in logistic regression models. RESULTS: The first case was published in 1980 but since 1993 the VigiBase clozapine-myocarditis IC has been significant; moreover, currently it is very strong (IC=6.0, IC005-IC995=5.9-6.1) and statistically significantly different from other antipsychotics. Of the 3274 different patients with myocarditis, 43.4% were non-serious cases, 51.8% were serious but non-fatal, and 4.8% were fatal. More than half (1621/3274) of the reports came from Australia, of which 69.2% were non-serious, 27.7% serious but non-fatal, and 3.1% fatal. Asian countries contributed only 41 cases. CONCLUSIONS: In pharmacovigilance studies, confounding factors may explain statistical associations, but the strength and robustness of these results are compatible with the hypothesis that myocarditis is definitively associated with early clozapine treatment (84% [1309/1560] and 5% [82/1560] in the first and second months). Myocarditis reports from Australia are over-represented to a major degree. Asian countries may be underreporting myocarditis to their drug agencies.
Assuntos
Antipsicóticos , Clozapina , Miocardite , Humanos , Clozapina/efeitos adversos , Farmacovigilância , Miocardite/induzido quimicamente , Miocardite/diagnóstico , Miocardite/epidemiologia , Antipsicóticos/efeitos adversos , Organização Mundial da SaúdeRESUMO
Introduction: The incidence of clozapine-associated myocarditis varies by country. These variations were explored in VigiBase, the World Health Organization's global database which has >25 million spontaneously reported adverse drug reaction (ADR) reports from 145 national drug agencies. Methods: On January 15, 2021, a search of VigiBase since inception focused on myocarditis in clozapine patients. The 3572 individual reports were studied using the standard VigiBase logarithmic measure of disproportionality called information component (IC). The IC measures the disproportionality between the expected and the reported rates. After duplicates were eliminated there were 3274 different patients with myocarditis studied in logistic regression models. Results: The first case was published in 1980 but since 1993 the VigiBase clozapine-myocarditis IC has been significant; moreover, currently it is very strong (IC=6.0, IC005IC995=5.96.1) and statistically significantly different from other antipsychotics. Of the 3274 different patients with myocarditis, 43.4% were non-serious cases, 51.8% were serious but non-fatal, and 4.8% were fatal. More than half (1621/3274) of the reports came from Australia, of which 69.2% were non-serious, 27.7% serious but non-fatal, and 3.1% fatal. Asian countries contributed only 41 cases. Conclusions: In pharmacovigilance studies, confounding factors may explain statistical associations, but the strength and robustness of these results are compatible with the hypothesis that myocarditis is definitively associated with early clozapine treatment (84% [1309/1560] and 5% [82/1560] in the first and second months). Myocarditis reports from Australia are over-represented to a major degree. Asian countries may be underreporting myocarditis to their drug agencies. (AU)
Introducción: La incidencia de la miocarditis asociada a clozapina varía en cada país, y esta variación se exploró en VigiBase, la base de datos de la Organización Mundial de la Salud con más de 25 millones de reportes de reacciones adversas a medicamentos de 145 agencias nacionales de medicamentos. Métodos: El 15 de enero del 2021, se llevó a cabo una búsqueda en VigiBase de las miocarditis y clozapina. El componente de información (CI) que es una medida logarítmica de desproporción se usó para estudiar los 3.752 reportes. Con modelos de regresión logística se estudió 3.274 pacientes diferentes después de eliminar los duplicados. Resultados: El primer caso fue publicado en 1980, pero desde 1993 el CI ha sido significativo; ahora es muy alto (CI=6,0; CI005-CI995=5,9-6,1), y estadísticamente significativo de otros antipsicóticos. En los 3.274 pacientes: el 43,4% de los casos fueron no graves, el 51,4% fueron casos graves, pero no letales y el 4,8% fueron casos letales. Australia contribuyó a más de la mitad de los casos (1.621/3.274): con un 69,2% de casos no graves, un 27,7% de casos graves, pero no letales y un 3,1% de casos letales. Cuarenta y un casos fueron de países de Asia. Conclusiones: Los factores de confusión pueden explicar asociaciones estadísticas pero el tamaño y la consistencia de estos resultados son compatibles con que la miocarditis está definitivamente asociada con el tratamiento inicial de la clozapina (el 84% [1.309/1.560] fueron durante el primer mes y otro 5% [82/1.560] durante el segundo). Australia está excesivamente representada, mientras que los países de Asia parecen reportar pocos casos a sus agencias de medicamentos. (AU)
Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Clozapina/efeitos adversos , Clozapina/metabolismo , Clozapina/toxicidade , Miocardite/induzido quimicamente , Organização Mundial da Saúde , FarmacovigilânciaRESUMO
INTRODUCTION: The incidence of clozapine-associated myocarditis varies by country. These variations were explored in VigiBase, the World Health Organization's global database which has >25 million spontaneously reported adverse drug reaction (ADR) reports from 145 national drug agencies. METHODS: On January 15, 2021, a search of VigiBase since inception focused on myocarditis in clozapine patients. The 3572 individual reports were studied using the standard VigiBase logarithmic measure of disproportionality called information component (IC). The IC measures the disproportionality between the expected and the reported rates. After duplicates were eliminated there were 3274 different patients with myocarditis studied in logistic regression models. RESULTS: The first case was published in 1980 but since 1993 the VigiBase clozapine-myocarditis IC has been significant; moreover, currently it is very strong (IC=6.0, IC005-IC995=5.9-6.1) and statistically significantly different from other antipsychotics. Of the 3274 different patients with myocarditis, 43.4% were non-serious cases, 51.8% were serious but non-fatal, and 4.8% were fatal. More than half (1621/3274) of the reports came from Australia, of which 69.2% were non-serious, 27.7% serious but non-fatal, and 3.1% fatal. Asian countries contributed only 41 cases. CONCLUSIONS: In pharmacovigilance studies, confounding factors may explain statistical associations, but the strength and robustness of these results are compatible with the hypothesis that myocarditis is definitively associated with early clozapine treatment (84% [1309/1560] and 5% [82/1560] in the first and second months). Myocarditis reports from Australia are over-represented to a major degree. Asian countries may be underreporting myocarditis to their drug agencies.
RESUMO
This review describes the geographical distribution, botanical data, popular use, chemical composition, pharmacological activities and genetic aspects related to Eugenia luschnathiana, a native Brazilian plant popularly known as "bay pitomba". E. luschnathiana leaves are characterized morphologically by the presence of a petiole, an attenuated base, acuminated apex, elliptical shape, and parallel venation. The major chemical compounds found in E. luschnathiana are sesquiterpenes. Literature reports showed that E. luschnathiana extracts have antioxidant properties and antimicrobial activity against Gram-negative and Gram-positive bacteria. The extractsfrom the leaf, fruit and stem, and a concentrated residual solution of its essential oil, displayed negligible toxicity. Lastly, a cytogenetic analysis indicated that some markers can be used for the study of genetic diversity, population structure, and genetic improvements. The information available on E. luschnathiana supports the hypothesis that this plant may be a source of compounds with promising pharmacological activity.
Esta revisión describe la distribución geográfica, datos botánicos, uso popular, composición química, actividad farmacológica y el análisis genético de Eugenia luschnathiana, una planta originaria del Brasil conocida popularmente como "pitomba da baía". Las hojas de E. luschnathiana se caracterizan por la presencia de pecíolo, base atenuada, ápice acuminado, forma elíptica y venación paralela. Su composición química presenta mayormente sesquiterpenos. Los informes en la literatura muestran que los extractos de E. luschnathiana presentan propiedades antioxidantes y actividad antimicrobiana contra las bacterias Gram-negativas y Gram-positivas. Los extractos de la hoja, fruto y tallo, y una solución residual concentrada del aceite esencial, presentaron baja toxicidad. Por último, un análisis citogenético indicó que algunos marcadores pueden utilizarse para estudios de diversidad genética, estructura poblacional y mejoramiento genético. Las informaciones disponibles acerca de E. luschnathiana proponen la hipótesis de que esta planta puede ser una fuente de compuestos con actividad farmacológica prometedora.
Assuntos
Óleos Voláteis/farmacologia , Extratos Vegetais/farmacologia , Eugenia/química , Anti-Infecciosos/farmacologia , Terpenos/análise , Bactérias/efeitos dos fármacos , Óleos Voláteis/química , Extratos Vegetais/genética , Extratos Vegetais/química , Folhas de Planta/química , Eugenia/genética , Medicina Tradicional , Anti-Infecciosos/químicaRESUMO
Objetivo: Evaluar el efecto protector del aceite de Plukenetia volubilis (Sacha Inchi) en la depresión inducida a ratones albinos. Materiales y métodos: Los ratones fueron divididos en 4 grupos y recibieron durante 10 días las siguientes sustancias: Grupo N°01(n=6) Vehículo 5 ml/Kg/12h, Grupo Nº 02 (n=6): Fluoxetina 10 mg/Kg/24horas, Grupo Nº 03 (n=6): Aceite de sacha inchi 1g/kg/12 horas, Grupo Nº 04 (n=6): Aceite de sacha inchi 3g/kg/12 horas. Luego, fueron sometidos a la prueba de Nado Forzado, sumergiéndolos en una piscina cilíndrica durante 6 minutos y registrando el tiempo de inmovilidad. Los ratones sometidos a la prueba de Sujeción de cola fueron distribuidos de la misma manera y administrados con las mismas sustancias para después de 10 días ser suspendidos por el tercio distal de la cola registrándose el tiempo de inmovilidad. Resultados: Los ratones que recibieron el aceite de Plukenetia volubilis a dosis de 1g/kg y 3 g/kg presentaron menor tiempo de inmovilidad respecto al control para ambas pruebas, sólo teniendo el grupo con dosis 3 g/kg significancia estadística. En el nado forzado el tiempo de inmovilidad con dosis de aceite de 1g/kg y 3 g/kg fue 184,7 s y 108,0 s, respectivamente. Para la prueba de Sujeción de cola el tiempo de inmovilidad fue 118,33 s y 63,33 s para dosis de 1g/kg y 3g/kg respectivamente. Conclusiones: El aceite de Sacha Inchi administrado por vía oral a dosis de 3g/kg demostró efecto protector similar a fluoxetina, frente a la depresión inducida en los modelos animales empleados. (AU)
Objective: Evaluate protective effect of Plukenetia volubilis oil (Sacha Inchi) on induced depression in albino mice. Materials and methods: Mice were divided into 4 groups and received the following substances during 10 days: Group N°1 (n = 6) Vehicle 5 ml/Kg/12h, Group N°2 (n = 6): Fluoxetine 10 mg/Kg/24h, Group N°3 (n = 6): Sacha inchi oil 1 g/kg /12h, Group N°4 (n = 6): Sacha inchi oil 3 g/ kg/12 h. Then, they were subject to Forced Swimming test, submerging them in a cylindrical pool for 6 minutes and the immobility time was recorded. The mice subjected to the tail suspension test were distributed in the same way and administered with the same substances, after 10 days being suspended by the distal third of the tail, recording the immobility time. Results: The mice that received the Plukenetia volubilis oil at a dose of 1 g/kg and 3 g/kg had a shorter immobility time regarding control for both tests, and only the group with a dose of 3 g/kg had statistical significance. In forced swimming the immobility time with oil doses of 1 g/kg and 3 g/kg was 184.7 s and 108.0 s, respectively. For Tail suspension test, the immobility time was 118.33 s and 63.33 s for doses of 1g/kg and 3g/kg, respectively. Conclusions: Sacha Inchi oil administered orally at a dose of 3g/kg showed a protective effect similar to fluoxetine, against induced depression in the animal model used. (AU)
Assuntos
Animais , Óleos/farmacologia , Depressão/tratamento farmacológico , CamundongosRESUMO
Patologías como la hipertensión, diabetes mellitus, infarto de miocardio y enfermedad cerebrovascular constituyen actualmente la principal causa de mortalidad incluso en varios países en vías de desarrollo. La efcacia de los inhibidores de la enzima conversora de angiotensina (IECAs) es bien conocida. Los antagonistas del receptor tipo 1 de angiotensina II (ARA-II) son alternativas farmacológicas importantes, debido a que poseen efectos sobre la función endotelial, remodelamiento del ventrículo izquierdo, microalbuminuria, etc. En esta revisión se comentan los algunos estudios que aportan datos sobre la efcacia de estos fármacos en el manejo de las enfermedades cardiovasculares
Hypertension, diabetes, myocardial infarction and cerebrovascular disease are now the leading cause of mortality even in developing countries. Angiotensin-converting enzyme inhibitors (ACE inhibitors) have a well documented effcacy. Angiotensin II type 1 receptor blockers (ARBs) are relevant pharmacological alternatives, based on its effects over endothelial function, left ventricular remodeling, microalbuminuria, etc. The aim of this review is to present evidence from some studies about the effcacy of ARBs in the treatment of cardiovascular diseases
Assuntos
Sistema Renina-Angiotensina , Diabetes Mellitus , Hipertensão , Preparações Farmacêuticas , Resultado do TratamentoRESUMO
Se analizan los motivos por los cuales el doping no encaja en la estructura del deporte, es potencialmente peligroso para la salud y se deben precisar conceptos. La clasificación farmacológica de las sustancias que no se deben usar en el deporte incluyen: hormonas peptídicas y derivados, hormonas esteroides anabólicas, estimulantes del sistema nervioso central, analgésicos, narcóticos (opioides), betabloqueadores, diuréticos, sustancias sujetas a ciertas restricciones y métodos de doping. Asimismo, se consideran los diversos efectos farmacodinámicos y farmacopatológicos, como también varios tipos de acciones disuasivas: preventivas, controladoras y sancionadoras.
The reasons why doping does not fit into the structure of sport, it is potentially dangerous for health and concepts must be specified are analyzed. The pharmacological classification of substances not to be used in sport include: peptide hormones and derivatives, anabolic steroid hormones, central nervous system stimulants, pain relievers, narcotics (opioids), beta-blockers, diuretics, substances subject to certain restrictions and methods of doping. Likewise, the various pharmacodynamic and pharmacopathological effects are considered, as well as various types of dissuasive actions: preventive, controlling and sanctioning.
